Annovis Bio Inc.

ANVS | NYSE

Price Alert Chart Builder DCF Calculator

$1.13

+$0.11 (+10.78%)

At close: Oct 30, 2026, 4:00 PM ET

$1.17

+$0.04 (+3.48%)

Pre-market: Nov 2, 2026, 4:00 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+10.78%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

39.2

+2.0 pts

Fundamentals Weak

Market Sentiment Bullish

Moat None

Sector Rank #548/1028 (Top 53%)

Full Analysis

Key Statistics

Market Data

Market Cap $48.23M

1D Range

1.01 1.17

52W Range

0.96 5.10

Valuation (TTM)

PE -0.63

PB -11.34

EV/EBITDA -0.60

Valuation (NTM)

Forward PE N/A

Forward PEG -0.08

Price Target $25.67

Cash Flow

FCF Yield -89.9%

SBC Adj. FCF Yield -91.9%

SBC Impact -2.3%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 48.5% | 9.3%

FCF 3Y | 5Y -21.9% | -20.1%

Returns

ROA -224.7%

ROE -686.0%

ROIC -400.4%

Financial Health

Net Cash

$18.73M

Current Ratio 2.95

Interest Coverage -31.16

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successf...

Sector Healthcare

Industry Biotechnology

Employees 7

IPO Date Jan 29, 2020

Website www.annovisbio.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$26.00

Upside

+2200.88%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞